Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical trial results for refinements of its original Ozempic and Wegovy drugs.

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best falling stocks to invest in right now.

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.